XML 113 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Narrative) (Details) - USD ($)
12 Months Ended
Jul. 27, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Accounts receivable   $ 923,000 $ 3,678,000    
Novartis Institutes for BioMedical Research, Inc. | Collaboration and License Agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Proceeds from collaborators $ 75,000,000        
Collaborative arrangement transaction price 95,100,000        
Collaborative arrangement, license fee 75,000,000        
Collaborative arrangement estimated reimbursable service costs $ 20,100,000        
Accounts receivable   0 2,200,000    
Deferred revenue   0 9,600,000    
Collaboration arrangement, commission fee, portion of gross proceeds, value         $ 1,500,000
Collaborative agreement, percent of initial recognition         2.00%
Amortization cost   $ 200,000 $ 600,000 $ 600,000